Glenmark launches world’s first nebulized triple therapy for COPD

Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness

Glenmark Pharmaceuticals, a global research-led pharmaceutical company, has announced the launch of the world’s first nebulized, fixed-dose triple therapy for Chronic Obstructive Pulmonary Disease (COPD).

The new therapies -- Nebzmart GFB Smartules and Glenmark Airz FB Smartules -- combine Glycopyrronium, Formoterol, and Budesonide, targeting airway obstruction, inflammation, and lung function deterioration in a single, easy-to-use nebulized form.

By minimizing the burden of multiple medications, the launch promises a breakthrough for COPD patients, particularly those who struggle with Metered Dose Inhalers (MDIs) or Dry Powder Inhalers (DPIs).

"At Glenmark, innovation is about reimagining and redefining how therapies reach patients. With Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world’s first nebulized triple therapy for COPD, we are transforming respiratory care,” said Alok Malik, President & Business Head, India Formulations, Glenmark Pharmaceuticals.

“This milestone reinforces Glenmark’s position as a front-runner in respiratory innovation and our commitment to making advanced, affordable, and accessible solutions for patients.”

Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness (dyspnea). The treatment was well-tolerated and showcased a strong safety profile, offering a simpler, more effective management option for COPD patients.

“This launch represents a significant advancement in the management of COPD and demonstrates our focus in strengthening global respiratory leadership,” said Dr Monika Tandon, Global Head of Clinical Development, Glenmark Pharmaceuticals.

“Nebulizer medications are easy to use in patients with COPD. The strong efficacy and safety demonstrated in the clinical study further support this novel treatment approach in COPD.”

Glenmark, which operates across Branded, Generics, and OTC segments with 11 manufacturing facilities across four continents and operations in over 80 countries, continues to focus on therapeutic areas including respiratory, dermatology, and oncology.